Trevogrumab (INN; development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. It is often used with Garetosmab. Trevogrumab is a fully human monoclonal antibody that functions as a selective inhibitor of myostatin (GDF8), a key negative regulator of skeletal muscle growth and mass. By binding and neutralizing myostatin, Trevogrumab prevents its interaction with activin type 2 receptors (ActRIIA/B), thereby reducing myostatin-mediated signaling and allowing increased muscle growth and preservation. This drug was developed by Regeneron Pharmaceuticals, Inc.
References
